CN112423747A - 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 - Google Patents

用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 Download PDF

Info

Publication number
CN112423747A
CN112423747A CN201980043623.8A CN201980043623A CN112423747A CN 112423747 A CN112423747 A CN 112423747A CN 201980043623 A CN201980043623 A CN 201980043623A CN 112423747 A CN112423747 A CN 112423747A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
administered
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980043623.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·豪尔顿
H·格伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spruce Biosciences Inc
Original Assignee
Spruce Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68295784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112423747(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Spruce Biosciences Inc filed Critical Spruce Biosciences Inc
Publication of CN112423747A publication Critical patent/CN112423747A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980043623.8A 2018-04-27 2019-04-26 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 Pending CN112423747A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862663951P 2018-04-27 2018-04-27
US62/663,951 2018-04-27
US201962822815P 2019-03-23 2019-03-23
US62/822,815 2019-03-23
PCT/US2019/029486 WO2019210266A1 (en) 2018-04-27 2019-04-26 Methods for treating testicular and ovarian adrenal rest tumors

Publications (1)

Publication Number Publication Date
CN112423747A true CN112423747A (zh) 2021-02-26

Family

ID=68295784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980043623.8A Pending CN112423747A (zh) 2018-04-27 2019-04-26 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法

Country Status (10)

Country Link
US (6) US11304950B2 (cg-RX-API-DMAC7.html)
EP (3) EP3784233B1 (cg-RX-API-DMAC7.html)
JP (1) JP7427655B2 (cg-RX-API-DMAC7.html)
CN (1) CN112423747A (cg-RX-API-DMAC7.html)
AU (3) AU2019260793B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020024062A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098562A1 (cg-RX-API-DMAC7.html)
ES (1) ES2991516T3 (cg-RX-API-DMAC7.html)
MX (1) MX2020011344A (cg-RX-API-DMAC7.html)
WO (1) WO2019210266A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210064407A (ko) 2014-01-21 2021-06-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
KR20220052927A (ko) 2019-07-19 2022-04-28 스프루스 바이오사이언시스 인코포레이티드 선천성 부신 증식증의 치료 방법
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ,インク. 多嚢胞性卵巣症候群を処置するための方法および組成物
US20240024330A1 (en) * 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) * 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
EP4402142A4 (en) * 2021-11-19 2025-07-23 Spruce Biosciences Inc CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0971528A (ja) * 1995-07-05 1997-03-18 Hayashibara Biochem Lab Inc 抗腫瘍剤
CN101516887A (zh) * 2006-09-20 2009-08-26 伊莱利利公司 作为crf1受体拮抗剂的噻唑吡唑并嘧啶类
US20100196389A1 (en) * 2008-04-30 2010-08-05 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer
CN106102740A (zh) * 2014-01-21 2016-11-09 纽罗克里生物科学有限公司 治疗先天性肾上腺增生的crf1受体拮抗剂

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
BR9307646A (pt) 1992-12-17 1999-05-25 Pfizer Pirrolopirimidinas como antagonistas de crf
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2168237T3 (es) 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
IL137019A (en) 1998-01-28 2010-11-30 Du Pont Pharm Co 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
FR2796380B3 (fr) 1999-07-15 2001-08-17 Sanofi Synthelabo Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
YU23602A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
HRP20010582A2 (en) 1999-12-08 2002-08-31 Pharmacia Corp Valdecoxib compositions
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
ES2282401T3 (es) 2001-03-13 2007-10-16 Bristol-Myers Squibb Pharma Company 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il) pirazolo - 1,5-a-1,3,5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor liberador de croticotropina.
WO2005020910A2 (en) 2003-08-27 2005-03-10 Pharmacia Corporation Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
US8304431B2 (en) 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP4926720B2 (ja) 2003-12-22 2012-05-09 スミスクライン ビーチャム (コーク) リミテッド Crf受容体アンタゴニストおよびそれらに関連する方法
JP2008503444A (ja) 2004-02-13 2008-02-07 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Crf受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
CA2556160A1 (en) 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
CN101142217B (zh) 2005-03-21 2010-12-08 伊莱利利公司 咪唑并哒嗪化合物
CA2644445A1 (en) * 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Inorganic selenium for treatment of benign tumors
CN101516835A (zh) 2006-07-19 2009-08-26 俄亥俄州立大学研究基金会 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
US8952207B2 (en) 2007-09-11 2015-02-10 The University Of Houston System Copper-catalyzed C—H bond arylation
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
TWI432435B (zh) 2008-10-02 2014-04-01 Lilly Co Eli 作為合成中間物之噻唑基-吡唑并嘧啶化合物及相關合成方法
EP4718073A3 (en) 2008-12-24 2026-07-29 Quest Diagnostics Investments LLC Mass spectrometry assay for congenital adrenal hyperplasia
US20110160168A1 (en) 2009-12-31 2011-06-30 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US9750568B2 (en) 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
JP2015516979A (ja) 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーHolsboermaschmeyer Neurochemie Gmbh Crh過剰活性を有する患者の治療に用いるためのcrhr1アンタゴニスト
ES2964948T3 (es) 2015-03-31 2024-04-10 May Health Us Inc Métodos y sistemas para la manipulación de tejidos ováricos
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
TWI803504B (zh) 2017-08-14 2023-06-01 美商雲杉生物科技股份有限公司 促皮質素釋放因子受體拮抗劑
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US20200255436A1 (en) 2019-02-12 2020-08-13 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
KR20220052927A (ko) 2019-07-19 2022-04-28 스프루스 바이오사이언시스 인코포레이티드 선천성 부신 증식증의 치료 방법
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ,インク. 多嚢胞性卵巣症候群を処置するための方法および組成物
EP4402142A4 (en) 2021-11-19 2025-07-23 Spruce Biosciences Inc CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0971528A (ja) * 1995-07-05 1997-03-18 Hayashibara Biochem Lab Inc 抗腫瘍剤
CN101516887A (zh) * 2006-09-20 2009-08-26 伊莱利利公司 作为crf1受体拮抗剂的噻唑吡唑并嘧啶类
US20100196389A1 (en) * 2008-04-30 2010-08-05 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer
CN106102740A (zh) * 2014-01-21 2016-11-09 纽罗克里生物科学有限公司 治疗先天性肾上腺增生的crf1受体拮抗剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUA-DONG CHEN ETAL.: "Ovarian Adrenal Rest Tumors Undetected by Imaging Studies and Identified at Surgery in Three Females with Congenital Adrenal Hyperplasia Unresponsive to Increased Hormone Therapy Dosage" *
苏喆;李燕虹;马华梅;张军;杜敏联: "先天性肾上腺皮质增生症21-羟化酶缺陷患者并发卵巢肾上腺残余瘤的临床特征分析" *

Also Published As

Publication number Publication date
US12576084B2 (en) 2026-03-17
US11304950B2 (en) 2022-04-19
EP4438124A3 (en) 2024-12-18
AU2019260793A1 (en) 2020-12-17
EP4643950A3 (en) 2026-01-14
JP7427655B2 (ja) 2024-02-05
AU2025204720A1 (en) 2025-07-10
EP3784233B1 (en) 2024-06-05
EP4438124A2 (en) 2024-10-02
AU2023203095A1 (en) 2023-06-08
US20250064812A1 (en) 2025-02-27
US20250195527A1 (en) 2025-06-19
MX2020011344A (es) 2021-02-09
US20250177404A1 (en) 2025-06-05
EP3784233C0 (en) 2024-06-05
US12569490B2 (en) 2026-03-10
US12569491B2 (en) 2026-03-10
WO2019210266A1 (en) 2019-10-31
CA3098562A1 (en) 2019-10-31
EP3784233A1 (en) 2021-03-03
JP2021522340A (ja) 2021-08-30
EP3784233A4 (en) 2022-03-02
EP4643950A2 (en) 2025-11-05
BR112020024062A2 (pt) 2021-02-09
US20250177403A1 (en) 2025-06-05
US20210038604A1 (en) 2021-02-11
ES2991516T3 (es) 2024-12-03
US20220211711A1 (en) 2022-07-07
AU2019260793B2 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
JP7427655B2 (ja) 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
US11964941B2 (en) 5-Bromo-indirubins
US20170196890A1 (en) Tgr5 agonist complexes for treating diabetes and cancer
US11505523B2 (en) HDAC8 inhibitors for treating cancer
TW202016112A (zh) 吡唑並嘧啶胺基環烷基類化合物及其醫療用途
CA2853729A1 (en) Novel compositions and methods for treating cancer
TW201922251A (zh) 抗癌劑
KR102275112B1 (ko) 5-브로모-인디루빈
TWI917338B (zh) C-c趨化介素受體第四型拮抗劑之晶形及其用途
TW202233613A (zh) 去氧胞苷激酶抑制劑之結晶型及其用途
HK40040045A (en) Methods for treating testicular and ovarian adrenal rest tumors
HK40040045B (en) Methods for treating testicular and ovarian adrenal rest tumors
US11213510B2 (en) Thioindirubins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination